Journal
CURRENT DRUG TARGETS
Volume 17, Issue 2, Pages 139-153Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1389450115666141110154621
Keywords
ATM; chemotherapy; glioma; inhibitor; radiotherapy; resistance; sensitization
Categories
Funding
- Compagnia S. Paolo, Turin, Italy [2010.1944]
- Fondazione Umberto Veronesi, Milano, Italy
Ask authors/readers for more resources
Genotoxic anticancer drugs explicate their effects damaging DNA, thus triggering a coordinated signal-transduction network called DNA Damage Response (DDR). Ataxia Telangiectasia Mutated (ATM) protein plays a central role in this response: activated by DNA damage, ATM phosphorylates itself and downstream effectors that arrest cell cycle allowing for DNA repair or, should DNA damage be too severe and not retrievable, inducing apoptosis. ATM is a worth-investigating target for tumor radio-and chemosensitization. During last years, pharmaceutical industries and research laboratories have developed a series of small molecules, capable to inhibit ATM with increasing specificity. Several preclinical studies have demonstrated that these inhibitors alone or in association with other treatments may improve therapeutic outcomes. In this review we discuss ATM inhibitors so far developed, focussing on recent acquisitions on their potential antineoplastic usefulness.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available